- Home
- NEXT vs ZLAB Comparison
NEXT vs ZLAB Comparison
Compare NEXT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXT
- ZLAB
- Stock Information
- Founded
- NEXT 2010
- ZLAB 2013
- Country
- NEXT United States
- ZLAB China
- Employees
- NEXT N/A
- ZLAB N/A
- Industry
- NEXT Oil & Gas Production
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- NEXT Energy
- ZLAB Health Care
- Exchange
- NEXT Nasdaq
- ZLAB Nasdaq
- Market Cap
- NEXT 1.4B
- ZLAB 1.8B
- IPO Year
- NEXT N/A
- ZLAB 2017
- Fundamental
- Price
- NEXT $5.93
- ZLAB $31.24
- Analyst Decision
- NEXT Hold
- ZLAB Strong Buy
- Analyst Count
- NEXT 1
- ZLAB 4
- Target Price
- NEXT $9.00
- ZLAB $52.50
- AVG Volume (30 Days)
- NEXT 1.1M
- ZLAB 976.3K
- Earning Date
- NEXT 11-11-2024
- ZLAB 11-12-2024
- Dividend Yield
- NEXT N/A
- ZLAB N/A
- EPS Growth
- NEXT N/A
- ZLAB N/A
- EPS
- NEXT N/A
- ZLAB N/A
- Revenue
- NEXT N/A
- ZLAB $322,711,000.00
- Revenue This Year
- NEXT N/A
- ZLAB $48.34
- Revenue Next Year
- NEXT N/A
- ZLAB $47.12
- P/E Ratio
- NEXT N/A
- ZLAB N/A
- Revenue Growth
- NEXT N/A
- ZLAB 28.16
- 52 Week Low
- NEXT $4.01
- ZLAB $13.48
- 52 Week High
- NEXT $8.52
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- NEXT 63.68
- ZLAB 70.41
- Support Level
- NEXT $5.35
- ZLAB $31.52
- Resistance Level
- NEXT $5.98
- ZLAB $36.60
- Average True Range (ATR)
- NEXT 0.27
- ZLAB 1.36
- MACD
- NEXT 0.04
- ZLAB 0.34
- Stochastic Oscillator
- NEXT 79.22
- ZLAB 58.60
About NEXT NextDecade Corporation
NextDecade Corp is a energy company predominantly engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The company provides a number of services depending on the individual needs of the customer. These include the supply and trade of LNG volumes, the creation of new natural gas infrastructure including pipeline and natural gas liquefaction facilities, treatment and processing of natural gas into LNG, as well as technical engineering and design services related to the development and execution of natural gas infrastructure, transporting, shipping and storage of LNG.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.